Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.61 |
| ▸ | PAK1 | Q13153 | 9/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20086209 | 0.91 | AXL (0.60) | AXLPAK1AAK1CDK8PAK4 | |
| SCHEMBL857669 | 0.83 | PAK1 (0.52) | AXLPAK1AAK1PAK4PKN1 | |
| SCHEMBL857957 | 0.83 | KIT (0.56) | AXLPAK1PAK4PKN1BTK | |
| SCHEMBL857113 | 0.83 | AXL (0.67) | AXLPAK1AAK1CDK8PAK4 | |
| SCHEMBL857953 | 0.83 | AXL (0.64) | AXLPAK1AAK1CDK8PAK4 | |
| SCHEMBL857763 | 0.82 | PAK1 (0.54) | AXLPAK1AAK1PAK4PKN1 | |
| SCHEMBL4014801 | 0.82 | AXL (0.60) | AXLPAK1AAK1CDK8MAPK1 | |
| SCHEMBL857149 | 0.81 | AXL (0.65) | AXLPAK1AAK1CDK8MAPK1 | |
| SCHEMBL858560 | 0.81 | AXL (0.67) | AXLPAK1AAK1CDK8PAK4 | |
| SCHEMBL857306 | 0.80 | PAK1 (0.48) | AXLPAK1AAK1PAK4PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | claimed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | AXL 861/4885PAK1 113/4885AAK1 120/4885 |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | AXL 38/4885PAK1 298/4885AAK1 2341/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AXL 1354/4885PAK1 187/4885AAK1 335/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AXL 1354/4885PAK1 187/4885AAK1 335/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AXL 1354/4885PAK1 187/4885AAK1 335/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AXL 1354/4885PAK1 187/4885AAK1 335/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | AXL 73/4885PAK1 562/4885AAK1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.